Autolane | $7,400,000 | (Dec 4, 2025)
Curvestone AI | $4,000,000 | (Dec 4, 2025)
Ridley | $6,400,000 | (Dec 4, 2025)
Certified by Founder
Lodge
Vima Therapeutics
start up
United States
- Cambridge, Massachusetts
- 30/05/2025
- Series A
- $60,000,000
Vima Therapeutics is a clinical-stage biotechnology company pioneering a new era in the treatment of dystonia and related movement disorders.
We are advancing VIM0423, a potential first-in-class oral therapy for dystonia, with the goal of helping individuals regain control of their movements by targeting the underlying cause of the disease.
Vima brings together a team of physicians, scientists, and drug developers with deep expertise in movement disorders and a shared commitment to deliver a meaningful oral therapy for patients.
- Industry Biotechnology Research
- Website https://vimatx.com/
- LinkedIn https://www.linkedin.com/company/vima-therapeutics/
Track Titan | $5,000,000 | (Dec 4, 2025)
Curi Bio | $10,000,000 | (Dec 4, 2025)
Unacast | $28,000,000 | (Dec 4, 2025)
Fin | $17,000,000 | (Dec 4, 2025)
Supper | $11,000,000 | (Dec 4, 2025)
Gradium | $70,000,000 | (Dec 4, 2025)
Juniper Biosciences | $40,000,000 | (Dec 4, 2025)
Heven AeroTech | $100,000,000 | (Dec 4, 2025)
PineAI | $25,000,000 | (Dec 4, 2025)